100 related articles for article (PubMed ID: 3828192)
1. Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers.
Taylor WB; Bateman DN
Br J Clin Pharmacol; 1987 Feb; 23(2):137-42. PubMed ID: 3828192
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of prochlorperazine in healthy young males.
Isah AO; Rawlins MD; Bateman DN
Br J Clin Pharmacol; 1991 Dec; 32(6):677-84. PubMed ID: 1768559
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and effects of prochlorperazine in elderly female volunteers.
Isah AO; Rawlins MD; Bateman DN
Age Ageing; 1992 Jan; 21(1):27-31. PubMed ID: 1553856
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers.
Avram MJ; Spyker DA; Henthorn TK; Cassella JV
Clin Pharmacol Ther; 2009 Jan; 85(1):71-7. PubMed ID: 18830225
[TBL] [Abstract][Full Text] [Related]
5. A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy.
Olver IN; Webster LK; Bishop JF; Clarke J; Hillcoat BL
Eur J Cancer Clin Oncol; 1989 Oct; 25(10):1457-61. PubMed ID: 2591437
[TBL] [Abstract][Full Text] [Related]
6. The prophylactic antiemetic efficacy of prochlorperazine and ondansetron in nasal septal surgery: a randomized double-blind comparison.
van den Berg AA
Anaesth Intensive Care; 1996 Oct; 24(5):538-45. PubMed ID: 8909662
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
[TBL] [Abstract][Full Text] [Related]
8. Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers.
Clark AM; Kriel RL; Leppik IE; Marino SE; Mishra U; Brundage RC; Cloyd JC
Epilepsia; 2013 Jun; 54(6):1099-105. PubMed ID: 23506041
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of procyclidine in man.
Whiteman PD; Fowle AS; Hamilton MJ; Peck AW; Bye A; Dean K; Webster A
Eur J Clin Pharmacol; 1985; 28(1):73-8. PubMed ID: 3987788
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride.
Krause W; Sauerbrey N; Gräf KJ
Eur J Clin Pharmacol; 1986; 31(2):165-8. PubMed ID: 3803415
[TBL] [Abstract][Full Text] [Related]
11. Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients.
Tashiro M; Naito T; Kagawa Y; Kawakami J
Ann Clin Biochem; 2018 May; 55(3):385-393. PubMed ID: 28853295
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route.
Finn A; Collins J; Voyksner R; Lindley C
J Clin Pharmacol; 2005 Dec; 45(12):1383-90. PubMed ID: 16291713
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration.
Jochemsen R; Wesselman JG; Hermans J; van Boxtel CJ; Breimer DD
Br J Clin Pharmacol; 1983; 16 Suppl 2(Suppl 2):285S-290S. PubMed ID: 6661374
[TBL] [Abstract][Full Text] [Related]
14. The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers.
Debbas NM; Jackson SH; Shah K; Abrams SM; Johnston A; Turner P
Br J Clin Pharmacol; 1986 Apr; 21(4):385-8. PubMed ID: 3707812
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration.
Ensing K; de Zeeuw RA; Nossent GD; Koëter GH; Cornelissen PJ
Eur J Clin Pharmacol; 1989; 36(2):189-94. PubMed ID: 2524387
[TBL] [Abstract][Full Text] [Related]
16. Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine.
Saadah HA
Headache; 1992 Mar; 32(3):143-6. PubMed ID: 1563946
[TBL] [Abstract][Full Text] [Related]
17. Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.
Sridhar KS; Krishan A; Samy TS; Sauerteig A; Wellham LL; McPhee G; Duncan RC; Anac SY; Ardalan B; Benedetto PW
Cancer Chemother Pharmacol; 1993; 31(6):423-30. PubMed ID: 8453681
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.
Collins RW; Jones JB; Walthall JD; Chisholm CD; Giles BK; Brizendine EJ; Cordell WH
Ann Emerg Med; 2001 Nov; 38(5):491-6. PubMed ID: 11679859
[TBL] [Abstract][Full Text] [Related]
19. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial.
Vinson DR; Drotts DL
Ann Emerg Med; 2001 Feb; 37(2):125-31. PubMed ID: 11174228
[TBL] [Abstract][Full Text] [Related]
20. Prochlorperazine induces akathisia in emergency patients.
Drotts DL; Vinson DR
Ann Emerg Med; 1999 Oct; 34(4 Pt 1):469-75. PubMed ID: 10499947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
